Regression of Fibrosis Following Hepatitis C Eradication

Scott L. Friedman

Regression of Fibrosis Following Hepatitis C Eradication

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Pages (from-to)	599-601
Number of pages	3
Journal	Gastroenterology and Hepatology
Volume	18
Issue number	10
State	Published - Oct 2022

Cite this

@article{00fdab4811574fe6ac151a5990edd629,

title = "Regression of Fibrosis Following Hepatitis C Eradication",

author = "Friedman, {Scott L.}",

note = "Funding Information: Dr Friedman has performed consulting activities for 89bio, Agomab, Axcella Health, Blade Therapeutics, Can-Fite Bio-Pharma, Escient Pharmaceuticals, Fate Therapeutics, Fibro-cor, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, HepGene, Insitro, Korro Bio, Merck, Metrea (Foresite), Morphic Therapeutic, NorthSea Therapeutics, Novartis, Ochre Bio, Pfizer, ProSciento Research, Resolution Therapeutics, Satellite Bio, Scholar Rock, Surrozen, and Yaqrit. He has had stock options (all <1% of company value) for Blade Therapeutics, Escient Pharmaceuticals, Galectin, Galmed, Genfit, Glympse Bio, HepGene, LifeMax, Meta-crine, Morphic Therapeutic, Nimbus, NorthSea Therapeutics, Satellite Bio, Scholar Rock, and Surrozen. He has owned stock in Intercept, Madrigal, and Group K. He has performed research activities for Morphic Therapeutic (contract studies), Novo Nordisk (contract studies), Abalone Bio (SBIR grant), Galmed (contract studies), Cincera Therapeutics (contract studies), and Pionyr.",

year = "2022",

month = oct,

language = "English",

volume = "18",

pages = "599--601",

journal = "Gastroenterology and Hepatology",

issn = "1554-7914",

publisher = "Gastro-Hep Communications, Inc.",

number = "10",

}

TY - JOUR

T1 - Regression of Fibrosis Following Hepatitis C Eradication

AU - Friedman, Scott L.

N1 - Funding Information: Dr Friedman has performed consulting activities for 89bio, Agomab, Axcella Health, Blade Therapeutics, Can-Fite Bio-Pharma, Escient Pharmaceuticals, Fate Therapeutics, Fibro-cor, Forbion, Galmed, Gordian Biotechnology, Glycotest, Glympse Bio, HepGene, Insitro, Korro Bio, Merck, Metrea (Foresite), Morphic Therapeutic, NorthSea Therapeutics, Novartis, Ochre Bio, Pfizer, ProSciento Research, Resolution Therapeutics, Satellite Bio, Scholar Rock, Surrozen, and Yaqrit. He has had stock options (all <1% of company value) for Blade Therapeutics, Escient Pharmaceuticals, Galectin, Galmed, Genfit, Glympse Bio, HepGene, LifeMax, Meta-crine, Morphic Therapeutic, Nimbus, NorthSea Therapeutics, Satellite Bio, Scholar Rock, and Surrozen. He has owned stock in Intercept, Madrigal, and Group K. He has performed research activities for Morphic Therapeutic (contract studies), Novo Nordisk (contract studies), Abalone Bio (SBIR grant), Galmed (contract studies), Cincera Therapeutics (contract studies), and Pionyr.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85139769294&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:85139769294

SN - 1554-7914

VL - 18

SP - 599

EP - 601

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

IS - 10

ER -